NCT00821184View on ClinicalTrials.gov

Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder

PHASE3TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Overactive Bladder
Interventions
DRUG

Vesicare (solifenacin)

5mg po qd

BEHAVIORAL

Vesicare (solifenacin) plus behavioral modification

5 mg dose po once daily plus behavioral modification

Trial Locations (1)

01805

Lahey Clinic, Burlington

Sponsors

Lead Sponsor

Lahey Clinic
All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Lahey Clinic

OTHER